AlgoTherapeutix develops targeted drug delivery systems for topical formulations that provide localized pain relief for complex pain conditions. This approach minimizes systemic side effects commonly associated with traditional pain medications, enhancing patient safety and comfort.
Funding
$39.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many patients experience complex pain conditions, such as Chemotherapy-Induced Peripheral Neuropathy (CIPN) and erythromelalgia, for which there are limited effective and approved therapies. Traditional pain medications often result in systemic side effects, reducing patient comfort and adherence. There is a need for targeted, non-opioid solutions that can provide localized pain relief without the drawbacks of systemic treatments.
Solution
AlgoTherapeutix (AlgoTx) is a clinical-stage biotechnology company focused on developing novel, non-opioid therapeutics for complex pain management. Their lead program, ATX01, is a topically administered formulation designed to selectively block pain signaling in peripheral sensory neurons. By targeting nociceptive sodium channels in the skin, ATX01 aims to deliver localized pain relief while minimizing systemic exposure and associated side effects. ATX01 is currently in Phase 2 clinical development for CIPN and erythromelalgia, with the goal of providing a first-in-class treatment option for patients with these difficult-to-treat conditions. The company prioritizes indications with no proven therapies, tailoring treatments to the specific needs of affected patients.
Target Audience
The primary target audience includes patients suffering from complex pain conditions like Chemotherapy-Induced Peripheral Neuropathy (CIPN) and erythromelalgia, as well as the oncologists, neurologists, and pain specialists who treat them.
Features
- Topical administration for direct blockade of pain messaging in peripheral sensory neurons
- Selective targeting of nociceptive sodium channels to minimize off-target effects
- Non-opioid mechanism of action to avoid the risks associated with opioid analgesics
- Minimized systemic exposure, reducing the potential for systemic side effects and drug interactions
- Phase 2 clinical trials underway for Chemotherapy-Induced Peripheral Neuropathy (CIPN) and erythromelalgia
- Potential for development in other pain indications beyond CIPN and erythromelalgia
- FDA Fast Track designation for ATX01